Smalley R V, Oldham R K
Drugs Exp Clin Res. 1986;12(1-3):31-9.
An analysis of recently conducted phase I trials of biological response modifiers (BRM), performed mainly under the sponsorship of the BRM Program of the National Cancer Institute, has led to the development of a format for performing such trials with these agents in the future. The evolution of this format and its use in ongoing phase I trials of recombinant beta and gamma interferons is discussed. An evaluation of the method will be undertaken at the conclusion of these studies.
主要在美国国立癌症研究所生物反应调节剂（BRM）项目赞助下开展的近期BRM一期试验分析，促成了未来使用这些药物进行此类试验的一种模式的形成。本文讨论了这种模式的演变及其在重组β和γ干扰素正在进行的一期试验中的应用。这些研究结束时将对该方法进行评估。
